PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio • Phase III pipeline portfolio: Global CNS disorders therapeutics market • Phase II pipeline portfolio: Global CNS disorders therapeutics market • Phase I pipeline portfolio: Global CNS disorders therapeutics market • Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by type of disease • Global depression drugs market • Global MS drugs market • Global schizophrenia drugs market • Global bipolar disorder therapeutics market • Global AD drugs market • Global epilepsy drugs market • Global PD drugs market PART 08: Geographical segmentation • CNS disorders therapeutics market in Americas • CNS disorders therapeutics market in EMEA • CNS disorders therapeutics market in APAC PART 09: Market drivers • Special regulatory designations for CNS disorders • New DMD approvals for AD, PD, and MS • Development of novel therapeutics using innovative technologies • High growth potential of mAbs PART 10: Impact of drivers PART 11: Market challenges • High failure rates of late-stage products in clinical trials • Growing use of non-invasive neuromodulation and seizure management devices • Unavailability of standard diagnostic methods • Increase in rehabilitation programs • Social stigma associated with CNS diseases PART 12: Impact of drivers and challenges PART 13: Market trends • Popularity of me-too drugs • Increased uptake of new-generation drugs • Reformulation of marketed drugs • Focus on regenerative therapies for CNS disorders • Increase in use of LAI antipsychotics PART 14: Vendor landscape0 • Competitive scenario0 • Key news3 • GlaxoSmithKline7 • Pfizer2 • Eli Lilly8 • Janssen Pharmaceuticals3 • Novartis8 • Other prominent vendors4 PART 15: Appendix4 • List of abbreviations4 PART 16: Explore Technavio6 List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global CNS disorders therapeutics market snapshot Exhibit 03: Impact of key customer segments on market 2015 Exhibit 04: Key buying criteria for CNS drugs 2015 Exhibit 05: Share of pipeline molecules in global CNS disorders therapeutics market Exhibit 06: Prevalence of dementia in various regions (millions) Exhibit 07: Revenues of top-selling CNS drugs (2013-2015) Exhibit 08: Global CNS disorders therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 09: Global CNS disorders therapeutics market 2015-2020 ($ billions) Exhibit 10: Impact of drivers and challenges on global CNS disorders therapeutics market Exhibit 11: Five forces analysis Exhibit 12: Global CNS disorders therapeutics market: Segmentation by application (2015-2020) Exhibit 13: Global CNS disorders therapeutics market: Segmentation by type of disease 2015 Exhibit 14: Global CNS disorders therapeutics market segmentation: Growth cycle analysis Exhibit 15: Global depression drugs market 2015-2020 ($ billions) Exhibit 16: Opportunity analysis of global depression drugs market Exhibit 17: Global MS drugs market 2015-2020 ($ billions) Exhibit 18: Opportunity analysis of global MS drugs market Exhibit 19: Global schizophrenia drugs market 2015-2020 ($ billions) Exhibit 20: Opportunity analysis of global schizophrenia drugs market Exhibit 21: Global bipolar disorder therapeutics market 2015-2020 ($ billions) Exhibit 22: Opportunity analysis of global bipolar disorder therapeutics market Exhibit 23: Population aged 60 years and above in millions (1950-2050) Exhibit 24: Global AD drugs market 2015-2020 ($ billions) Exhibit 25: Opportunity analysis of global AD drugs market Exhibit 26: Global epilepsy drugs market 2015-2020 ($ billions) Exhibit 27: Percentage share of marketed antiepileptic drugs based on mechanism of action Exhibit 28: Opportunity analysis of global epilepsy drugs market Exhibit 29: Global PD drugs market 2015-2020 ($ billions) Exhibit 30: Opportunity analysis of global PD drugs market Exhibit 31: Global CNS disorders therapeutics market: Geography outlook (2015-2020) Exhibit 32: Global CNS disorders therapeutics market: Geography outlook 2015 Exhibit 33: Global CNS disorders therapeutics market segmentation by geography: Market growth lifecycle analysis 2015 Exhibit 34: Global CNS disorders market revenue/growth outlook in different countries/regions 2015 Exhibit 35: Global CNS disorders therapeutics market segmentation by geography 2015-2020 ($ billions) Exhibit 36: Opportunity analysis of CNS disorders therapeutics market in Americas Exhibit 37: Projected prevalence rates of AD in Americas (2010-2050) (millions) Exhibit 38: CNS disorders therapeutics market in Americas 2015-2020 ($ billions) Exhibit 39: Percentage share of CNS disorders therapeutics market in Americas by geography 2015 Exhibit 40: Opportunity analysis of CNS disorders therapeutics market in EMEA Exhibit 41: CNS disorders therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 42: Opportunity analysis of CNS disorders therapeutics market in APAC Exhibit 43: CNS disorders therapeutics market in APAC 2015-2020 ($ billions) Exhibit 44: Few of the late-stage mAbs under development for various CNS disorders Exhibit 45: Impact of drivers Exhibit 46: Common disorders that co-exist with bipolar disorder Exhibit 47: Impact of drivers and challenges Exhibit 48: Impact of trends on global CNS disorders therapeutics market Exhibit 49: Planned clinical trials of iPS cell-based therapies Exhibit 50: Position of key vendors in the global CNS disorders therapeutics market 2015 Exhibit 51: Geographical presence of key vendors Exhibit 52: Company portfolio analysis in global CNS disorders therapeutics market 2016-2020 Exhibit 53: GlaxoSmithKline: Profile Exhibit 54: GlaxoSmithKline: Sales of top-selling CNS drugs ($ millions) Exhibit 55: GlaxoSmithKline: Metrics analysis Exhibit 56: GlaxoSmithKline: Growth strategy matrix Exhibit 57: GlaxoSmithKline: Opportunity assessment Exhibit 58: Pfizer: Profile Exhibit 59: Sales of CNS drugs ($ millions) Exhibit 60: Pfizer: Metrics analysis Exhibit 61: Pfizer: Growth strategy matrix Exhibit 62: Pfizer: Opportunity assessment Exhibit 63: Eli Lilly: Profile Exhibit 64: Eli Lilly: Sales of top-selling CNS drugs ($ millions) Exhibit 65: Eli Lilly: Metrics analysis Exhibit 66: Eli Lilly: Growth strategy matrix Exhibit 67: Eli Lilly: Opportunity assessment Exhibit 68: Janssen Pharmaceuticals: Profile Exhibit 69: Janssen Pharmaceuticals: Sales of CNS drugs ($ millions) Exhibit 70: Janssen Pharmaceuticals: Metrics analysis Exhibit 71: Janssen Pharmaceuticals: Growth strategy matrix Exhibit 72: Janssen Pharmaceuticals: Opportunity assessment Exhibit 73: Novartis: Profile Exhibit 74: Novartis: Sales of few major CNS drugs ($ millions) Exhibit 75: Novartis: Metrics analysis Exhibit 76: Novartis growth strategy matrix Exhibit 77: Novartis: Opportunity assessment

GlaxoSmithKline, Pfizer, Eli Lilly, Janssen Pharmaceuticals, and Novartis. Other Prominent Vendors in the market are: AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer Pharmaceuticals, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, H. Lundbeck, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Ipsen, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lupin, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis , Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, Pierre Fabre, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals , SAGE Therapeutics, Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceuticalc, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.